Clinical Edge Journal Scan

PsA remission depends on patient perception and is multidimensional


 

Key clinical point: Patients with psoriatic arthritis (PsA) were more likely to report remission if they perceived an acceptable disease state, psoriasis remission, and a lower impact of PsA on global quality of life.

Major finding: Patient-reported PsA remission was associated with the achievement of 9-question Psoriatic Arthritis Impact of Disease score of ≤4 (odds ratio [OR] 4.58; P < .05), perception of psoriasis remission (OR 4.51; P < .05), and global quality of life score (OR 0.55; P < .001).

Study details: Findings are from a cross-sectional survey by the National Psoriasis Foundation including 834 patients with psoriasis or PsA.

Disclosures: This study did not receive any funding. Several authors declared serving as research or principal investigators, advisors, or consultants for several sources.

Source: Gondo G et al. Demographic and clinical factors associated with patient-reported remission in psoriatic arthritis. Dermatol Ther (Heidelb). 2022;12(8):1885-1895 (Jul 21). Doi: 10.1007/s13555-022-00770-6

Recommended Reading

Study suggests psoriasis and PsA are underdiagnosed in underserved groups
MDedge Rheumatology
Biosimilar-to-biosimilar switches deemed safe and effective, systematic review reveals
MDedge Rheumatology
FDA approves adalimumab-bwwd biosimilar (Hadlima) in high-concentration form
MDedge Rheumatology
PsA: Bimekizumab is well tolerated and effective in the long-term
MDedge Rheumatology
Golimumab effective as second-line anti-TNFα treatment in the real-world
MDedge Rheumatology
Nail disease and dactylitis influence treatment response in patients receiving etanercept or methotrexate
MDedge Rheumatology
Nail dystrophy predicts response to secukinumab in PsA patients with axial manifestations
MDedge Rheumatology
Clinically meaningful improvement in PRO with risankizumab vs placebo in PsA
MDedge Rheumatology
Robust and consistent improvement in HRQoL with guselkumab
MDedge Rheumatology
Long-term safety and efficacy of risankizumab in PsA
MDedge Rheumatology